[go: up one dir, main page]

MX2010003925A - Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p). - Google Patents

Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p).

Info

Publication number
MX2010003925A
MX2010003925A MX2010003925A MX2010003925A MX2010003925A MX 2010003925 A MX2010003925 A MX 2010003925A MX 2010003925 A MX2010003925 A MX 2010003925A MX 2010003925 A MX2010003925 A MX 2010003925A MX 2010003925 A MX2010003925 A MX 2010003925A
Authority
MX
Mexico
Prior art keywords
sphingosine
phosphate
receptor modulators
compositions
amino
Prior art date
Application number
MX2010003925A
Other languages
English (en)
Other versions
MX337152B (es
Inventor
Colleen Ruegger
Michael Ambuhl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40032615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003925(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010003925A publication Critical patent/MX2010003925A/es
Publication of MX337152B publication Critical patent/MX337152B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

La presente invención se refiere a composiciones estables que comprenden un modulador del receptor de fosfato de esfingosina-1 (S1P), adecuadas para utilizarse como una forma de dosificación. Los moduladores del receptor S1P son típicamente análogos de esfingosina, tales como 2-amino-propano-1 ,3-diol 2-sustituido, o derivados de 2-amino-propanol, por ejemplo, un compuesto que comprende un grupo de la Fórmula Y.
MX2010003925A 2007-10-12 2008-10-09 Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p). MX337152B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97948207P 2007-10-12 2007-10-12
PCT/US2008/079264 WO2009048993A2 (en) 2007-10-12 2008-10-09 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators

Publications (2)

Publication Number Publication Date
MX2010003925A true MX2010003925A (es) 2010-05-05
MX337152B MX337152B (es) 2016-02-15

Family

ID=40032615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003925A MX337152B (es) 2007-10-12 2008-10-09 Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p).

Country Status (32)

Country Link
US (6) US8673918B2 (es)
EP (7) EP2653154A1 (es)
JP (2) JP6034000B2 (es)
KR (3) KR101600098B1 (es)
CN (1) CN101820916A (es)
AR (1) AR068986A1 (es)
AU (1) AU2008310846C1 (es)
BR (1) BRPI0818161B8 (es)
CA (2) CA2699788C (es)
CL (1) CL2008003003A1 (es)
CO (1) CO6270342A2 (es)
DK (1) DK2952177T3 (es)
EC (1) ECSP10010169A (es)
ES (2) ES2545361T3 (es)
HR (1) HRP20150838T1 (es)
HU (2) HUE027696T2 (es)
IL (3) IL204514B (es)
JO (2) JOP20080436B1 (es)
MA (1) MA31799B1 (es)
MX (1) MX337152B (es)
MY (1) MY159358A (es)
NZ (1) NZ600355A (es)
PE (2) PE20090799A1 (es)
PL (2) PL2952177T3 (es)
PT (2) PT2952177T (es)
RU (1) RU2010118457A (es)
SG (2) SG10201800085XA (es)
SI (2) SI2952177T1 (es)
TN (1) TN2010000136A1 (es)
TW (1) TW200927142A (es)
WO (1) WO2009048993A2 (es)
ZA (1) ZA201001819B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2278960T2 (sl) 2008-03-17 2020-02-28 Actelion Pharmaceuticals Ltd. Režim odmerjanja za selektivni agonist receptorja sip1
EP2326325B1 (en) 2008-08-18 2014-11-12 Novartis AG Azetidine derivative for the treatment of peripheral neuropathies
DK4098256T5 (da) * 2008-12-22 2025-07-21 Novartis Ag Doseringsregime for en s1p-receptoragonist
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
CA2797042A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Fingolimod in the form of a solid solution
WO2011131370A1 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh Melt-granulated fingolimod
CN101973898B (zh) * 2010-09-09 2013-06-19 南京明生医药技术有限公司 2-对辛基苯乙基-2-氨基丙二醇衍生物及其应用
HUE045612T2 (hu) * 2011-01-07 2020-01-28 Novartis Ag Immunszuppresszáns készítmények
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
ES2388273B1 (es) * 2011-03-16 2013-10-01 Consejo Superior De Investigaciones Científicas (Csic) Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
MX2014004813A (es) * 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP2014129238A (ja) * 2012-12-28 2014-07-10 Lion Corp エトドラク含有固形製剤
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2996681B1 (en) * 2013-05-13 2019-12-18 Synthon B.V. Pharmaceutical composition comprising fingolimod
CA2920758A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
US20150141520A1 (en) * 2013-11-18 2015-05-21 Chandrasekhar Kandi Stabilized pharmaceutical compositions of fingolimod and process for preparation thereof
HUE046273T2 (hu) 2014-02-13 2020-02-28 Incyte Corp Ciklopropilaminok mint LSD1 inhibitorok
WO2015123408A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
SMT201900620T1 (it) 2014-02-13 2020-01-14 Incyte Corp Ciclopropilammine come inibitori di lsd1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CA2942236C (en) * 2014-04-10 2023-08-29 Novartis Ag Dosage form of siponimod
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CN113559075A (zh) * 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
US10583087B2 (en) * 2015-04-28 2020-03-10 Astellas Pharma Inc. Pharmaceutical composition for oral administration
HUE070538T2 (hu) 2015-08-12 2025-06-28 Incyte Holdings Corp Egy LSD1 inhibitor sói
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
CA3000186A1 (en) * 2015-10-02 2017-04-06 Mylan Inc. Stable formulations of fingolimod
CA3021678A1 (en) * 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
JP7365409B2 (ja) 2018-06-28 2023-10-19 エイアールエックス エルエルシー 溶解性単位用量膜構造物を製造するための分配方法
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CA3114751A1 (en) 2018-10-05 2020-04-09 Fuji Chemical Industries Co., Ltd. Porous silica particle composition
JP7739452B2 (ja) * 2021-04-14 2025-09-16 エルジー・ケム・リミテッド 粒度が制御されたスフィンゴシン－１－リン酸受容体アゴニストを含む医薬組成物
WO2022220593A1 (ko) * 2021-04-14 2022-10-20 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제를 포함하는 직접 타정용 약제학적 조성물
WO2024126409A1 (en) 2022-12-12 2024-06-20 Synthon B.V. Pharmaceutical composition of siponimod

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
DE69524962D1 (de) 1994-08-22 2002-02-14 Welfide Corp Benzolderivate und deren medizinische verwendung
US5616621A (en) * 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
SI0812588T1 (en) 1995-12-28 2005-02-28 Mitsubishi Pharma Corporation Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
PT990440E (pt) 1997-02-27 2009-02-05 Novartis Ag Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido
ES2226110T3 (es) 1997-04-04 2005-03-16 Mitsubishi Pharma Corporation Compuestos de 2-aminopropano-1,3-diol, su uso medico, e intermedios para sintetizarlos.
JP4627356B2 (ja) 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
NZ533997A (en) 2000-07-13 2005-11-25 Sankyo Co Amino alcohol derivatives
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
MXPA04002679A (es) 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
EP1575964B1 (en) 2002-01-18 2009-11-11 Merck & Co., Inc. N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
EP2617711A1 (en) 2002-09-19 2013-07-24 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivatives, salts thereof and immunosuppressive agents
JP4564918B2 (ja) 2003-02-18 2010-10-20 杏林製薬株式会社 アミノホスホン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
AR043987A1 (es) 2003-04-08 2005-08-17 Novartis Ag Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1
TW200503783A (en) 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
FR2854549B1 (fr) 2003-05-06 2005-06-24 Actis Ets Tete pour l'equipement d'un bras de robot destine a realiser une operation d'ebavurage ou de cardage
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
EP2644195A1 (en) 2003-05-19 2013-10-02 Irm Llc Immunosuppressant Compounds and Compositions
CA2529318C (en) 2003-06-24 2013-09-17 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
BRPI0413151A (pt) 2003-08-28 2006-10-03 Novartis Ag derivados de amino propanol
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
WO2006102611A2 (en) 2005-03-24 2006-09-28 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
BRPI0717570B8 (pt) * 2006-09-26 2021-05-25 Novartis Ag composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção

Also Published As

Publication number Publication date
IL255737A (en) 2018-01-31
JP2011500583A (ja) 2011-01-06
HRP20150838T1 (hr) 2015-11-06
MY159358A (en) 2016-12-30
SG187458A1 (en) 2013-02-28
IL277999A (en) 2020-11-30
EP2952177A1 (en) 2015-12-09
US8673918B2 (en) 2014-03-18
RU2016138157A (ru) 2018-12-13
KR20170021904A (ko) 2017-02-28
ZA201001819B (en) 2010-12-29
HK1213768A1 (en) 2016-07-15
US20170368001A1 (en) 2017-12-28
EP2653154A1 (en) 2013-10-23
MX337152B (es) 2016-02-15
JOP20210187A1 (ar) 2023-01-30
CN101820916A (zh) 2010-09-01
CL2008003003A1 (es) 2009-05-15
KR20100091179A (ko) 2010-08-18
CA2699788C (en) 2016-06-14
DK2952177T3 (da) 2021-04-26
RU2010118457A (ru) 2011-11-20
PL2952177T3 (pl) 2021-07-19
US20160296481A1 (en) 2016-10-13
MA31799B1 (fr) 2010-10-01
WO2009048993A3 (en) 2010-05-06
PT2952177T (pt) 2021-04-26
TN2010000136A1 (en) 2011-09-26
CA2925175A1 (en) 2009-04-16
EP2952177B1 (en) 2021-01-20
IL255737B (en) 2020-10-29
CA2699788A1 (en) 2009-04-16
WO2009048993A2 (en) 2009-04-16
AU2008310846B2 (en) 2012-06-21
SI2952177T1 (sl) 2021-07-30
AU2008310846A1 (en) 2009-04-16
ES2545361T3 (es) 2015-09-10
BRPI0818161B1 (pt) 2020-12-22
PE20130309A1 (es) 2013-03-30
HUE027696T2 (en) 2016-10-28
PE20090799A1 (es) 2009-07-20
EP2209493A2 (en) 2010-07-28
NZ600355A (en) 2013-02-22
KR20160025633A (ko) 2016-03-08
SI2465492T1 (sl) 2015-12-31
KR101710845B1 (ko) 2017-02-27
JOP20080436B1 (ar) 2023-03-28
US20100267675A1 (en) 2010-10-21
HUE053835T2 (hu) 2021-07-28
BRPI0818161B8 (pt) 2021-05-25
US20170151195A1 (en) 2017-06-01
US20140142192A1 (en) 2014-05-22
US20150165046A1 (en) 2015-06-18
EP3120833A1 (en) 2017-01-25
US9399066B2 (en) 2016-07-26
ES2864671T3 (es) 2021-10-14
JP6034000B2 (ja) 2016-11-30
TW200927142A (en) 2009-07-01
KR101600098B1 (ko) 2016-03-04
IL204514B (en) 2018-01-31
EP2465492A1 (en) 2012-06-20
CO6270342A2 (es) 2011-04-20
AR068986A1 (es) 2009-12-23
EP3733161A1 (en) 2020-11-04
EP2465492B1 (en) 2015-07-01
SG10201800085XA (en) 2018-02-27
RU2016138157A3 (es) 2020-02-10
BRPI0818161A2 (pt) 2017-05-16
PT2465492E (pt) 2015-10-15
ECSP10010169A (es) 2010-06-29
EP3733162A1 (en) 2020-11-04
PL2465492T3 (pl) 2015-11-30
AU2008310846C1 (en) 2022-10-06
JP2015091822A (ja) 2015-05-14

Similar Documents

Publication Publication Date Title
JOP20210187A1 (ar) تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)
MX2019012750A (es) Moduladores del receptor s1p para el tratamiento de esclerosis multiple.
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
ECSP088854A (es) Moduladores bencimidazolicos de vr1
SV2010003737A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
DOP2010000229A (es) Compuestos que comprenden un grupo ciclobutoxi
BRPI0409680A (pt) análogos de fosfonato anti-cáncer
MX2010001446A (es) Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple.
TN2010000125A1 (en) Substituted biphenyl gpr40 modulators
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
MX2020001259A (es) Composiciones farmaceuticas que comprenden un modulador de s1p.
CR11362A (es) Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol
WO2012071212A3 (en) Novel phosphonic acids as s1p receptor modulators
CL2008001500A1 (es) Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
BR112012023039A2 (pt) pirimidina substituída como um antagonista de receptor prostaglandina d2
MX2009012683A (es) Benzamidas utiles como moduladores del receptor s1p.
TW200613317A (en) Steroid prodrugs with androgenic action
TH103571A (th) องค์ประกอบซึ่งประกอบด้วยตัวปรับสฟิงโกชีน 1 ฟอสเฟด (s1p) รีเซพเตอร์
HK1143526A (en) Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
ECSP099805A (es) Nuevos derivados de ácido dicarboxílico como agonistas de los receptores de s1p1
CR8977A (es) Dosis altas de formulaciones de ibandronato

Legal Events

Date Code Title Description
FG Grant or registration